

COVID-19 Outbreak Control and Prevention State Cell Health and Family Welfare Department Govt. of Kerala

DM Wayanad Institute of Medical Sciences DM WIMS Virology BSL – 2 Lab ICMR Approved - VBSLDMWIMSK

DM WIMS

DM Wayanad Institute of Medical Sciences, Nasceta Nagar, Meppadi (P.O), Wayanad -673577, Kerala, India. Phone: +91-8111881053, e-mail: lab@dmwims.com, www.dmwims.com

Laboratory is approved by Indian Council of Medical Research, Government of India through Department of Health and Family Welfare, Government of Kerala.

COVID-19 RT PCR TEST REPORT							
WIMS MRD No				141608			
Date and time of reporting				25.02.2022 06:30PM			
Referred by- Name of facility/self				DM WIMS			
Specimen Details							
Date & Time of Sample Collection				25.02.2022 03.00PM			
Date & Time of Testing				25.02.2022 03.30PM			
Date & Time of Reporting				25.02.2022 06:30PM			
Reporting Details							
Patient ID	SRF ID	Patient name & Address	Age	Sex	Specimen type	Type of test	COVID-19 Result
P- 2180/202	2180/WYD/	Joe Peter Sebastian	5	Male	Nasal Swab	RT PCR	Negative
2021632	2022021629	Chakkalakal, Kakkavayal (PO),					
		Kalpetta, Wayanad, Kerala					
Mob: 9003173069							
Prepared by			· La				
Swapna K Raju							
Senior Microbiologist				Carlo			
Checked & Approved by				010 (6)			
Dr. Deepthy B J				th Jugar			
		of Microbiology	00				
DM WIMS V	Virology BSL	-2 Lab					

Note: The results relate only to the specimens tested and should be correlated with clinical findings. Interpretation guidance:

- 1. Negative Result-implies the absence of selective amplification for E gene and N gene in the moment of performing the process, therefore it is considered as Negative result
- 2. Positive Result-implies the selective amplification for E gene and N gene in the moment of performing the process, therefore it is considered as Positive result.
- 3. $Test-Quantiplus_Version2$; $Negative-No\ Cq\ value\ detected\ in\ 40\ amplification$
- 4. Testing of referred clinical specimens was considered on the basis of request/referral received from/ through state surveillance officer (SSO) of concerned State Integrated Disease Surveillance Programme/any other health care facility affirming requirements of the case definition/s or by self.
- 5. Repeat sampling and testing of lower respiratory specimen is strongly recommended in severe or progressive disease. The repeat specimens may be considered after a gap of 2-4 days after the collection of the first specimen for additional testing if required.
- 6. A positive alternate pathogen does not necessarily rule out either, as little is yet known about the role of coinfections.
- 7. Please note that these results are not to be used for any thesis or presentations or publication in any journal without the prior permission of the Director General, ICMR.



